<DOC>
	<DOCNO>NCT00988065</DOCNO>
	<brief_summary>This trial conduct study potential hypersensitivity symptom time initial exposure sugammadex upon repeat exposure , since unknown whether frequency severity hypersensitivity symptom may worsen repeat exposure prolong period . In total 450 participant ( healthy subject ) randomize receive one three study treatment : three repeat dos either sugammadex 4 mg/kg , sugammadex 16 mg/kg , placebo . Participants receive one dose study treatment Day 8 , Day 36 , Day 78 study order determine safety treatment dose .</brief_summary>
	<brief_title>Sugammadex Hypersensitivity Study ( Study P06042 )</brief_title>
	<detailed_description>All subject admit study center day schedule dose leave unit morning day dose . In case suspect hypersensitivity symptom , healthy subject remain confined study center sign symptom regress , subject stable , investigator consider safe subject leave study center . Four site participate trial .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>1855 year age Serum tryptase &lt; =11.4 mcg/L fast triglyceride level within normal limit Safety laboratory test vital sign must within normal limit Screening electrocardiogram must clinically acceptable parameter within normal limit Body Mass Index 19 32 kg/m^2 Females must agree use contraceptives Other certain administrative criterion describe protocol Females pregnant intend become pregnant Subjects would able participate optimally study , opinion investigator Certain surgical medical condition , recent infection , mental instability Positive test certain drug history alcohol drug abuse Positive test hepatitis B , hepatitis C , Human Immunodeficiency Virus ( HIV ) Blood donation past 60 day A history unexplained reaction hypersensitivity reaction previous surgery and/or anesthesia History anaphylaxis cause , suspect history hypersensitivity cyclodextrins , multiple drug hypersensitivity Heavy smoker Received certain medication past History allergy , hypersensitivity , intolerance epinephrine great risk develop adverse reaction epinephrine administration Other certain administrative criterion describe protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>